EP1515955A4 - Chemical process - Google Patents

Chemical process

Info

Publication number
EP1515955A4
EP1515955A4 EP03742050A EP03742050A EP1515955A4 EP 1515955 A4 EP1515955 A4 EP 1515955A4 EP 03742050 A EP03742050 A EP 03742050A EP 03742050 A EP03742050 A EP 03742050A EP 1515955 A4 EP1515955 A4 EP 1515955A4
Authority
EP
European Patent Office
Prior art keywords
chemical process
chemical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03742050A
Other languages
German (de)
French (fr)
Other versions
EP1515955A2 (en
Inventor
Amogh Boloor
Mui Cheung
Jeffrey Alan Stafford
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline LLC
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of EP1515955A2 publication Critical patent/EP1515955A2/en
Publication of EP1515955A4 publication Critical patent/EP1515955A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
EP03742050A 2002-06-17 2003-06-17 Chemical process Withdrawn EP1515955A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38934902P 2002-06-17 2002-06-17
US389349P 2002-06-17
PCT/US2003/019211 WO2003106416A2 (en) 2002-06-17 2003-06-17 Chemical process

Publications (2)

Publication Number Publication Date
EP1515955A2 EP1515955A2 (en) 2005-03-23
EP1515955A4 true EP1515955A4 (en) 2006-05-03

Family

ID=29736629

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03742050A Withdrawn EP1515955A4 (en) 2002-06-17 2003-06-17 Chemical process

Country Status (10)

Country Link
US (1) US20060252943A1 (en)
EP (1) EP1515955A4 (en)
JP (1) JP2005529954A (en)
CN (1) CN1688553A (en)
AU (1) AU2003276125B2 (en)
CA (1) CA2489648A1 (en)
IL (1) IL165286A0 (en)
MX (1) MXPA04012860A (en)
PL (1) PL374963A1 (en)
WO (1) WO2003106416A2 (en)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
HRP20050089B1 (en) 2002-07-29 2015-06-19 Rigel Pharmaceuticals Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
US20040242568A1 (en) 2003-03-25 2004-12-02 Syrrx, Inc. Dipeptidyl peptidase inhibitors
JP4886511B2 (en) 2003-07-30 2012-02-29 ライジェル ファーマシューティカルズ， インコーポレイテッド Method for treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
EP1506967B1 (en) 2003-08-13 2007-11-21 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2005019345A1 (en) 2003-08-25 2005-03-03 Kaneka Corporation Curing composition with improved heat resistance
EP1699777B1 (en) 2003-09-08 2012-12-12 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
MXPA06010571A (en) 2004-03-15 2007-02-16 Takeda Pharmaceutical DIPEPTIDIL PEPTIDASA INHIBITORS.
WO2006020564A1 (en) * 2004-08-09 2006-02-23 Smithkline Beecham Corporation Pyrimidin derivatives for the treatment of multiple myeloma
EP1828192B1 (en) 2004-12-21 2014-12-03 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
CN101115761B (en) 2005-01-19 2012-07-18 里格尔药品股份有限公司 Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
AU2006254840B2 (en) 2005-06-08 2012-08-02 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
ME02005B (en) 2005-09-14 2012-08-31 Takeda Pharmaceuticals Co Dipeptidyl peptidase inhibitors for treating diabetes
CN101360723A (en) 2005-09-16 2009-02-04 武田药品工业株式会社 Process for preparing pyrimidinedione derivatives
MX2008006379A (en) * 2005-11-29 2009-03-03 Smithkline Beecham Corp Treatment method.
EP1954281B1 (en) 2005-11-29 2011-03-09 GlaxoSmithKline LLC Cancer treatment method
ES2622493T3 (en) 2006-02-24 2017-07-06 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibiting the JAK route
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
NZ580671A (en) 2007-04-16 2012-03-30 Hutchison Medipharma Entpr Ltd Pyrimidine derivatives
MX2010011463A (en) 2008-04-16 2011-06-03 Portola Pharm Inc 2, 6-diamino- pyrimidin- 5-yl-carboxamides as syk or jak kinases inhibitors.
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
CA2728893C (en) 2008-04-16 2017-03-14 Portola Pharmaceuticals, Inc. Inhibitors of syk protein kinase
JP2011518219A (en) 2008-04-22 2011-06-23 ポートラ ファーマシューティカルズ， インコーポレイテッド Inhibitors of protein kinases
WO2011039648A1 (en) 2009-09-30 2011-04-07 Glaxo Wellcome Manufacturing Pte Ltd. Methods of administration and treatment
EP2490536A4 (en) * 2009-10-23 2013-04-17 Glaxo Wellcome Mfg Pte Ltd Compositions and processes
WO2011058179A1 (en) 2009-11-16 2011-05-19 Ratiopharm Gmbh 5- (4- (n- (2, 3 -dimethyl- 2h- indazol- 6 -yl) -n-methylamino) pyrimidin- 2 -ylamino) -2 -methylbenzenesulfonamide
WO2011069053A1 (en) 2009-12-04 2011-06-09 Teva Pharmaceutical Industries Ltd. Process for the preparation of pazopanip hcl and crystalline forms of pazopanib hcl
AU2011323484B2 (en) 2010-11-01 2016-10-06 Portola Pharmaceuticals, Inc. Benzamides and nicotinamides as Syk modulators
US20130317029A1 (en) 2010-11-01 2013-11-28 Portola Pharmaceuticals, Inc. Oxypyrimidines as syk modulators
WO2012061428A2 (en) 2010-11-01 2012-05-10 Portola Pharmaceuticals, Inc. Nicotinamides as jak kinase modulators
WO2012073254A1 (en) * 2010-11-29 2012-06-07 Hetero Research Foundation A process for the preparation of pazopanib using novel intermediate
CN102060848B (en) * 2010-12-09 2013-09-18 天津药物研究院 Preparation and application of aromatic amine substituted pyrimidine derivatives
SG11201402570QA (en) 2011-11-23 2014-06-27 Portola Pharm Inc Pyrazine kinase inhibitors
CN103319410B (en) * 2012-03-22 2016-04-06 天津药物研究院 A kind of synthetic method of indazole compound
CN103373989B (en) * 2012-04-28 2016-04-13 上海医药工业研究院 The preparation method of the intermediate of pazopanib hydrochloride
CN103373963B (en) * 2012-04-28 2015-07-08 上海医药工业研究院 Intermediate of pazopanib hydrochloride and preparation method of intermediate of pazopanib hydrochloride
WO2014058921A2 (en) 2012-10-08 2014-04-17 Portola Pharmaceuticals, Inc. Substituted pyrimidinyl kinase inhibitors
WO2014097152A1 (en) * 2012-12-17 2014-06-26 Ranbaxy Laboratories Limited Process for the preparation of pazopanib or salts thereof
EP2935250B1 (en) 2012-12-17 2018-03-28 Sun Pharmaceutical Industries Limited Process for the preparation of pazopanib or salts thereof
CN103232443B (en) * 2013-02-01 2014-12-10 天津药物研究院 Indazole derivative crystal and its preparation method and use
CN103450085B (en) * 2013-08-15 2015-11-18 凯莱英医药集团（天津）股份有限公司 A kind of preparation method of pazopanib hydrochloride key intermediate
US10730859B2 (en) 2013-11-05 2020-08-04 Laurus Labs Limited Process for the preparation of pazopanib or a pharmaceutically acceptable salt thereof
CN106565688B (en) * 2016-11-11 2018-08-31 重庆医科大学 Pazopanib dimer and its preparation method and application
CN110028495B (en) * 2019-05-24 2019-12-03 济南爱思医药科技有限公司 The preparation method of pazopanib hydrochloride
CN116554106A (en) * 2023-04-28 2023-08-08 扬州市普林斯医药科技有限公司 Preparation method of 6-chloro-2-methyl-2H-indazole-5-amine

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3755332A (en) * 1971-07-01 1973-08-28 Ciba Geigy Corp Substituted 4 indazolaminoquinolines
US20020052386A1 (en) * 2000-02-17 2002-05-02 Armistead David M. Kinase inhibitors
WO2002059110A1 (en) * 2000-12-21 2002-08-01 Glaxo Group Limited Pyrimidineamines as angiogenesis modulators

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9918035D0 (en) * 1999-07-30 1999-09-29 Novartis Ag Organic compounds
ATE396978T1 (en) * 1999-10-07 2008-06-15 Amgen Inc TRIAZINE KINASE INHIBITORS
JP3711443B2 (en) * 2000-10-25 2005-11-02 セイコーエプソン株式会社 Inkjet recording device
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
GB0206215D0 (en) * 2002-03-15 2002-05-01 Novartis Ag Organic compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3755332A (en) * 1971-07-01 1973-08-28 Ciba Geigy Corp Substituted 4 indazolaminoquinolines
US20020052386A1 (en) * 2000-02-17 2002-05-02 Armistead David M. Kinase inhibitors
WO2002059110A1 (en) * 2000-12-21 2002-08-01 Glaxo Group Limited Pyrimidineamines as angiogenesis modulators

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
K. V. AUWERS ET AL, BERICHTE DER DEUTSCHEN CHEMISCHEN GESELLSCHAFT, vol. 53/II, 1920, pages 1211 - 1232, XP002363030 *
M. BENCHIDMI ET AL, J. HET. CHEM., vol. 16, 1979, pages 1599 - 1603, XP002363031 *
M. CHEUNG ET AL, J. ORG. CHEM., vol. 68, no. 10, 2003, pages 4093 - 4095, XP002363051 *
T. KAMETANI ET AL, J. HET. CHEM., vol. 14, 1977, pages 1175 - 1182, XP002363032 *
T.J. SCHWAN ET AL, J. HET. CHEM., vol. 20, 1983, pages 1351 - 1353, XP002362736 *

Also Published As

Publication number Publication date
WO2003106416A3 (en) 2004-05-06
JP2005529954A (en) 2005-10-06
MXPA04012860A (en) 2005-09-20
CA2489648A1 (en) 2003-12-24
PL374963A1 (en) 2005-11-14
AU2003276125A1 (en) 2003-12-31
AU2003276125B2 (en) 2007-05-17
IL165286A0 (en) 2005-12-18
CN1688553A (en) 2005-10-26
EP1515955A2 (en) 2005-03-23
WO2003106416A2 (en) 2003-12-24
US20060252943A1 (en) 2006-11-09

Similar Documents

Publication Publication Date Title
TWI316058B (en) Chemical process
IL165286A0 (en) Chemical process
GB0324791D0 (en) Chemical process
GB0324793D0 (en) Chemical process
GB0205016D0 (en) Process
GB0320793D0 (en) Chemical process
GB0201505D0 (en) Process
GB0218041D0 (en) Chemical process
GB0202564D0 (en) Process
GB0229803D0 (en) Chemical process
GB0201378D0 (en) Process
GB0216412D0 (en) Chemical process
GB0210370D0 (en) Chemical process
GB0202563D0 (en) Process
GB0222833D0 (en) Chemical process
GB0302648D0 (en) Chemical process
GB0313920D0 (en) Chemical process
GB0221243D0 (en) Chemical process
GB2387596B (en) Process
HU0302972D0 (en) Chemical process
GB0313911D0 (en) Chemical process
GB0324545D0 (en) Chemical process
GB0313919D0 (en) Chemical process
GB0313918D0 (en) Chemical process
HU0300278D0 (en) Chemical process

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20041216

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

RAX Requested extension states of the european patent have changed

Extension state: LV

Payment date: 20041216

Extension state: LT

Payment date: 20041216

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1076804

Country of ref document: HK

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SMITHKLINE BEECHAM CORPORATION

RIN1 Information on inventor provided before grant (corrected)

Inventor name: STAFFORD, JEFFREY ALAN

Inventor name: CHEUNG, MUI

Inventor name: BOLOOR, AMOGH

A4 Supplementary search report drawn up and despatched

Effective date: 20060320

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: GLAXOSMITHKLINE LLC

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100105

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1076804

Country of ref document: HK